[
  {
    "newsArray": [
      { "siteName": "医药魔方" },
      { "siteName": "腾讯网" },
      { "siteName": "医药魔方" }
    ],
    "summary": "美国FDA暂停了宜联生物与BioNTech合作开发的抗体偶联药物BNT326/YL202的临床试验，因为该药物可能带来严重的健康风险，已在1期试验中导致3名患者死亡 ...",
    "id": "8aXuIP7JBkN",
    "order": 1718836605200,
    "createdAt": "2024-06-19T22:36:45.000Z",
    "publishDate": "2024-06-19T22:36:45.200Z",
    "title": "3名患者死亡，FDA暂停一个ADC药物临床试验",
    "type": "topic",
    "up": false,
    "date": "2024-06-20 06:36:45",
    "uuid": "73b3cc1b-50f5-4916-8ef5-9809a578a259"
  }
]
